Camizestrant (AZD9833) is an orally available and selective estrogen receptor (ER) antagonist with antineoplastic activity.
Camizestrant (AZD9833) is an orally available and selective estrogen receptor (ER) antagonist with antineoplastic activity.
AZD9833 is demonstrated to be a highly potent selective estrogen receptor degraders (SERD) that shows a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines.[2]
A stringent control of lipophilicity ensures that AZD9833 has favorable physicochemical and preclinical pharmacokinetic properties for oral administration. AZD9833 is potent in vivo activity in mouse xenograft models.[2]
[1] Bernard Christophe Barlaam, et al. US20180111931A1. [2] James S Scott, et al. J Med Chem. 2020 Dec 10;63(23):14530-14559.
动态评分
0.0